Amyloidosis overview

Revision as of 17:10, 20 July 2016 by Megan Merlo (talk | contribs)
Jump to navigation Jump to search

Amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Primary amyloidosis
Secondary amyloidosis
Familial amyloidosis
Wild-type (senile) amyloidosis
Cardiac amyloidosis
Beta-2 microglobulin related amyloidosis
Gelsolin related amyloidosis
Lysozyme amyloid related amyloidosis
Leucocyte cell-derived chemotaxin 2 related amyloidosis
Fibrinogen A alpha-chain associated amyloidosis

Pathophysiology

Causes

Differentiating Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Amyloidosis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Amyloidosis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Amyloidosis overview

CDC on Amyloidosis overview

Amyloidosis overview in the news

Blogs on Amyloidosis overview

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Amyloidosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

In medicine, amyloidosis refers to a variety of conditions in which amyloid proteins are abnormally deposited in organs and/or tissues, causing disease. A protein is amyloid if, due to an alteration in its secondary structure, it takes on a particular insoluble form, called the beta-pleated sheet. Approximately 25 different proteins are known that can form amyloid in humans. Most of them are constituents of the plasma.Different amyloidoses can be systemic (affecting many different organ systems) or organ-specific. Some are inherited, due to mutations in the precursor protein. Other, secondary forms are due to different diseases causing overabundant or abnormal protein production-such as with over production of immunoglobulin light chains in multiple myeloma (termed AL amyloid), or with continuous overproduction of acute phase proteins in chronic inflammation (which can lead to AA amyloid).

Historical Perspective

Classification

The more common types of amyloid include AL, AA, Aβ, ATTR and Aβ2M from the 15 biologically distinct forms.

Pathophysiology

Amyloid is a pathological extracellular deposit composed predominantly of amyloid fibrils. Amyloidosis is disease caused by amyloid deposits in the tissues. The deposits may be local or systemic in distribution and acquired or hereditary in aetiology. All patients with amyloidosis have amyloid deposits in their tissues when they first present clinically. Clinical impairment progresses as amyloid deposits increase in size, and regression of amyloid is associated with clinical improvement and survival. Secondary amyloidoses is far more common than the primary amyloidoses.

Causes

Amyloidosis is can be systemic or organ specific. In systemic amyloidosis, secondary variety (AL, AA) is far more common than the primary one.

Differentiating Amyloidosis from other Diseases

Amyloidosis needs to be differentiated from acute myocarditis, bronchiectasis, multiple myeloma and other systemic diseases .

Risk Factors

Risk factors have not yet been identified.

Screening

Natural History, Complications and Prognosis

The complications of amyloidosis include hyposplenism, malabsorbtion syndrome, myopathy, proximal renal tubular acidosis and renal failure. The severity the disease depends on the organs that are affected. When the heart and kidney are involved, it may lead to organ failure and death.

Natural History

Complications

Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Symptoms depend on the organs affected by the deposits. These organs can include the tongue, intestines, skeletal and smooth muscles, nerves, skin, ligaments, heart, liver, spleen, and kidneys.

Physical Examination

Common findings in amyloidosis include petechiae, ecchymosis, parotid gland enlargement, increased intra ocular pressure, enlarged tongue, hepatomegaly, carpal tunnel syndrome and Raynaud phenomenon.

Laboratory Findings

Laboratory findings in amyloidosis include elevated erythrocyte sedimentation rate, increased BUN level, serum creatinine, protein, casts, or fat bodies in urine. Serum troponin, B-type natriuretic peptide, and beta-2-microglobulin are prognostic markers for heart failure. Amyloid deposits can be identified histologically by Congo red staining and viewing under polarized light where amyloid deposits produce a distinctive 'apple green birefringence'. Alternatively, thioflavin T stain may be used. An abdominal fat pad aspiration, rectal mucosa biopsy, or bone marrow biopsy can help confirm the diagnosis. They reveal positive findings in 80% patients.

Electrocardiogram

EKG findings in a case of amyloidosis include an abnormal rhythm and low voltage recordings.

Chest X Ray

The X ray findings in a case of amyloidosis include a coin lesion.

MRI

Cardiac MRI is used when echocardiogram fails to differentiate amyloidosis from hypertrophic cardiomyopathy.

Echocardiography

Echocardiography is useful to evaluate extent of heart involvement. The common findings include thickened ventricular wall and wall motion abnormalities.

Other Imaging Findings

Tissue Doppler and myocardial strain rate imaging has been proven to be very sensitive for the assessment of myocardial dysfunction in restrictive cardiomyopathy. Serum amyloid P component (SAP) scans have been developed which can anatomically localize amyloid deposits.

Other Diagnostic Studies

Treatment

There is no treatment for primary amyloidosis. The initial target in the treatment of this disorder is to correct the organ failure, as the disease is discovered at an advanced stage.

Medical Therapy

Surgery

Prevention

References

Template:WH Template:WS